Comparison of Fenofibric Acid Bioavailability From ABT-335 Capsules
Information source: Abbott
Information obtained from ClinicalTrials.gov on February 12, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: ABT-335 (Drug)
Phase: Phase 1
Status: Not yet recruiting
Sponsored by: Abbott Overall contact:
Debra M Schuerr, BS, Phone: 847-937-5748, Email: debra.m.schuerr@abbott.com
Summary
The purpose of this study is to evaluate the safety and compare the bioavailability of
fenofibric acid from 2 different dosage strengths of ABT-335.
Clinical Details
Official title: Comparison of Fenofibric Acid Bioavailability From 45 mg and 135 mg Strength ABT-335 Capsules
Study design: Treatment, Randomized, Open Label, Crossover Assignment
Primary outcome: To determine the bioavailability of ABT-335 in healthy subjects as measured by timed pharmacokinetic blood draws from pre-dose (0 hour) to 120 hours post doseTo evaluate the safety and tolerability of ABT-335 in healthy adults after single dosage
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- A condition of general good health
- BMI 18 to 29
Exclusion Criteria:
- Currently enrolled in another clinical study
- Females who are pregnant or breast-feeding
Locations and Contacts
Debra M Schuerr, BS, Phone: 847-937-5748, Email: debra.m.schuerr@abbott.com
Abbott Clinical Pharmacology Research Unit, Waukegan, Illinois 60064, United States
Additional Information
Starting date: February 2009
Last updated: February 6, 2009
|
